Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel. Show more
Building 7, Tel Aviv-Yafo, 6158002, Israel
Market Cap
11.45M
52 Wk Range
$1.35 - $5.88
Previous Close
$1.59
Open
$1.56
Volume
47,934
Day Range
$1.54 - $1.60
Enterprise Value
1.083M
Cash
10.37M
Avg Qtr Burn
N/A
Insider Ownership
11.50%
Institutional Own.
9.03%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nebokitug Details Primary Sclerosing Cholangitis | Phase 2 Update |